cyfendus

Cyfendus is an **adjuvanted anthrax vaccine** indicated for post-exposure prophylaxis against disease following suspected or confirmed exposure to *Bacillus anthracis*, the bacterium causing anthrax. It is administered in individuals aged 18 to 65 years in conjunction with recommended antibacterial drugs. Cyfendus uses additional adjuvant technology (CPG 7909), a toll-like receptor 9 (TLR9) agonist oligodeoxynucleotide, which boosts Th1-type immune responses and accelerates protective immunity compared to previous formulations. This vaccine was developed to address public health risks and bioterrorism preparedness by enhancing immunogenicity and reducing dosing requirements versus older anthrax vaccines. Approval followed pivotal Phase III and II clinical studies demonstrating consistency, immunogenicity, safety, and efficacy in acceleration of antibody responses and improved protection timelines. Developed by Emergent BioSolutions, Cyfendus supersedes legacy anthrax vaccine formulations as the US FDA-approved next generation anthrax vaccine, now procured for national stockpiling[1][2][3][4][8].

Brand names

Cyfendus

Other names

Anthrax Vaccine Adsorbed, Adjuvantednext generation anthrax vaccine